These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 25382021)

  • 61. Review: Combination umeclidinium/vilanterol improved health status more than umeclidinium in COPD.
    Stanbrook MB
    Ann Intern Med; 2015 Dec; 163(12):JC10. PubMed ID: 26666800
    [No Abstract]   [Full Text] [Related]  

  • 62. Umeclidinium-vilanterol inhaler approved for COPD.
    Traynor K
    Am J Health Syst Pharm; 2014 Feb; 71(3):174. PubMed ID: 24429003
    [No Abstract]   [Full Text] [Related]  

  • 63. Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
    Bateman ED; Mahler DA; Vogelmeier CF; Wedzicha JA; Patalano F; Banerji D
    Expert Rev Respir Med; 2014 Jun; 8(3):357-79. PubMed ID: 24802656
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.
    Kempsford R; Norris V; Siederer S
    Pulm Pharmacol Ther; 2013 Apr; 26(2):256-64. PubMed ID: 23232038
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Current optimization of combined therapy for chronic obstructive pulmonary disease].
    Popova EN
    Ter Arkh; 2015; 87(12):107-110. PubMed ID: 27022659
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Vilanterol trifenatate for the treatment of COPD.
    Malerba M; Radaeli A; Montuschi P; Morjaria JB
    Expert Rev Respir Med; 2016 Jul; 10(7):719-31. PubMed ID: 27143334
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Umeclidinium Plus Vilanterol Versus Placebo, Umeclidinium, or Vilanterol Monotherapies for Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials.
    Wang L; Zhai CJ; Liu Y; Liu Y; Jiang SJ
    Clin Drug Investig; 2016 Nov; 36(11):865-875. PubMed ID: 27539612
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dose response of umeclidinium administered once or twice daily in patients with COPD: a pooled analysis of two randomized, double-blind, placebo-controlled studies.
    Donohue JF; Kalberg C; Shah P; Beerahee M; Mehta R; Gunawan R; Church A
    J Clin Pharmacol; 2014 Nov; 54(11):1214-20. PubMed ID: 24895108
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi.
    Calzetta L; Rogliani P; Facciolo F; Rendina E; Cazzola M; Matera MG
    Eur J Pharmacol; 2017 Oct; 812():147-154. PubMed ID: 28716723
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Estimating individual treatment effects on COPD exacerbations by causal machine learning on randomised controlled trials.
    Verstraete K; Gyselinck I; Huts H; Das N; Topalovic M; De Vos M; Janssens W
    Thorax; 2023 Oct; 78(10):983-989. PubMed ID: 37012070
    [TBL] [Abstract][Full Text] [Related]  

  • 72. ▼Relvar Ellipta for COPD.
    Drug Ther Bull; 2014 Jun; 52(6):66-9. PubMed ID: 24904005
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Sensory-mechanical effects of a dual bronchodilator and its anticholinergic component in COPD.
    O'Donnell DE; Elbehairy AF; Faisal A; Neder JA; Webb KA;
    Respir Physiol Neurobiol; 2018 Jan; 247():116-125. PubMed ID: 28993264
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Umeclidinium for treating COPD: an evaluation of pharmacologic properties, safety and clinical use.
    Manickam R; Asija A; Aronow WS
    Expert Opin Drug Saf; 2014 Nov; 13(11):1555-61. PubMed ID: 25294427
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study.
    Mehta R; Hardes K; Brealey N; Tombs L; Preece A; Kelleher D
    Int J Chron Obstruct Pulmon Dis; 2015; 10():15-23. PubMed ID: 25565796
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Fixed combination of long-acting bronchodilators in COPD].
    Steurer J
    Praxis (Bern 1994); 2015 Oct; 104(22):1221. PubMed ID: 26953373
    [No Abstract]   [Full Text] [Related]  

  • 77. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
    Martinez FJ; Boscia J; Feldman G; Scott-Wilson C; Kilbride S; Fabbri L; Crim C; Calverley PM
    Respir Med; 2013 Apr; 107(4):550-9. PubMed ID: 23332861
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
    Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial.
    Bleecker ER; Lötvall J; O'Byrne PM; Woodcock A; Busse WW; Kerwin EM; Forth R; Medley HV; Nunn C; Jacques L; Bateman ED
    J Allergy Clin Immunol Pract; 2014; 2(5):553-61. PubMed ID: 25213048
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
    Agustí A; de Teresa L; De Backer W; Zvarich MT; Locantore N; Barnes N; Bourbeau J; Crim C
    Eur Respir J; 2014 Mar; 43(3):763-72. PubMed ID: 24114969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.